Investors

Overview

Corporate Profile

At Gamida Cell, we are cell therapy pioneers working to turn cells into powerful therapeutics. Our proprietary technology leverages nicotinamide (NAM), which plays a key role in the metabolic reprogramming of cells, to expand the number of cells and enhance cellular functionality and phenotype. Our therapeutic product and candidates aim to offer potentially curative treatment options for patients living with blood cancers.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

View All
Nov 27, 2023

Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023

Read More
Nov 20, 2023

Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

Read More
Nov 14, 2023

Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update

Read More
Nov 04, 2023

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Read More
Nov 01, 2023

Gamida Cell to Report Third Quarter 2023 Financial Results

Read More
Oct 16, 2023

Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201

Read More
Oct 09, 2023

Gamida Cell Issues Update on Israel Operations

Read More
Oct 07, 2023

Gamida Cell Statement Regarding Attacks on Israel

Read More
Oct 02, 2023

Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa

Read More
Sep 28, 2023

Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Read More
Sep 27, 2023

First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)

Read More
Aug 31, 2023

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference

Read More
Aug 14, 2023

Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update

Read More
Aug 01, 2023

Gamida Cell to Report Second Quarter 2023 Financial Results

Read More
Jul 11, 2023

Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)

Read More
Jun 14, 2023

Gamida Cell To Host Investor Day

Read More
May 31, 2023

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

Read More
May 31, 2023

Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting

Read More
May 22, 2023

Gamida Cell Appoints Terry Coelho as CFO

Read More
May 15, 2023

Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update

Read More
Corporate Fact Sheet
Corporate Presentation

Investor & Media Contact

Ryan Pugliares
Gamida Cell Ltd.
IRPR@gamida-cell.com